News + Studies

Continue

September 11, 2017  |  News

FDA Accepts Adello’s Biosimilar Biologics License Application (BLA) for a Proposed Filgrastim Biosimilar

Read More

January 22, 2017  |  News

The Pure-Play's Guide To Branding Biosimilars

Read More

November 15, 2016  |  News

Therapeutic Proteins International Renames Company to Adello Biologics, LLC

Read More

February 15, 2016  |  News

Therapeutic Proteins International Announces Appointment of Michael W. Washabaugh, Ph.D. as Chief Scientific Officer

Read More

November 04, 2015  |  News

Therapeutic Proteins International Announces Appointment of Peter F. Moesta, Ph.D. As Chief Executive Officer

Read More

November 03, 2015  |  Studies

Pharmacokinetic and pharmacodynamic properties of a new biosimilar filgrastim TPI G-CSF in comparison to the marketed reference filgrastim Neupogen®: a double-blind, single-dose, two-period crossover trial

Read More